Accounts Payable

6 Months Ended

Jun. 30, 2019

Accounts Payable

Accounts Payable

5.Accounts Payable

As of June 30, 2019, Current Liabilities included accounts payable of $0.4 million, comprised primarily of amounts owed for external research expenses of $0.2 million, legal expenses of $0.1 million and other payables of $0.1 million. As of December 31, 2018, Current Liabilities included accounts payable of $0.6 million, comprised primarily of preclinical expenses of $0.2 million, amounts owed to the Company’s clinical research organizations for our clinical trials for prexigebersen in AML and CML of $0.1 million, an annual license maintenance fee of $0.1 million, manufacturing costs of $0.1 million and other payables of $0.1 million.